ContraFect to Present at the World Anti-Microbial Resistance Congress 2019
November 05 2019 - 6:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including lysins and amurin peptides, as new medical
modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that Cara Cassino,
MD, ContraFect’s Chief Medical Officer and Executive Vice President
of Research & Development was invited to discuss the exebacase
superiority design trial at the World Anti-Microbial Resistance
Congress 2019, to be held from November 7-8, 2019, in Washington,
D.C. Exebacase, a DLA, is the first non-traditional antibacterial
to report positive results from a randomized, double-blind,
placebo-controlled Phase 2 superiority design trial in patients
with Staphylococcus aureus bacteremia, including endocarditis. The
talk, entitled “Novel Trial Designs for Non-Traditional
Anti-infectives – Lessons Learned from the Exebacase Superiority
Design Trial,” will take place at 3:15 p.m. ET on Thursday,
November 7, 2019.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of DLAs, which
include lysins and amurin peptides. Lysins are a new class of DLAs
which are recombinantly produced antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics. Amurin peptides are a new class of DLAs,
which exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, including Pseudomonas
aeruginosa (P. aeruginosa), Acinetobacter baumannii, and
Enterobacter species. We believe that the properties of our lysins
and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as methicillin-resistant Staph
aureus (MRSA) and P. aeruginosa, which can cause serious infections
such as bacteremia, pneumonia and osteomyelitis. We have completed
a Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis, with our lead lysin candidate,
exebacase, which is the first lysin to enter clinical studies in
the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
About Exebacase (CF-301):
Exebacase is a recombinantly-produced lysin
(cell wall hydrolase enzyme) with potent bactericidal activity
against Staph aureus, a major cause of blood stream infections
(BSIs) also known as bacteremia. It has a novel, rapid, and
specific mechanism of bactericidal action against Staph aureus. By
targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to exebacase. We
have completed a Phase 2 superiority design clinical study with
exebacase which evaluated its safety, tolerability, efficacy and PK
when used in addition to standard-of-care (SOC) antibiotics for the
treatment of Staph aureus bacteremia, including endocarditis, in
adult patients. In a pre-specified analysis of MRSA-infected
patients, the clinical responder rate at day 14 in patients treated
with exebacase was 43% higher than the clinical responder rate in
patients treated with SOC antibiotics alone (74% for patients
treated with exebacase compared to 31% for patients treated with
SOC antibiotics alone (p=0.010)). Additionally, among United States
MRSA patients discharged alive from the hospital, the median length
of stay was reduced by four days and the 30-day all cause
readmission rate was reduced to 16% from 31% in patients treated
with exebacase. We believe exebacase has the potential to be a
first-in-class treatment for Staph aureus bacteremia. Exebacase was
licensed from The Rockefeller University and is being developed at
ContraFect.
Forward-Looking Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the planned
presentation, ContraFect’s ability to discover and develop DLAs as
new medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, ContraFect’s ability to address
life threatening infections using its therapeutic product
candidates from its DLA platform, whether lysins are a new class of
DLAs which are recombinantly produced, antimicrobial proteins with
a novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics, whether amurins exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, whether the properties of ContraFect’s lysins and
amurins will make them suitable for targeting antibiotic-resistant
organisms, such as Staph aureus and P. aeruginosa, and the
potential for exebacase to be a first-in-class treatment for Staph
aureus bacteremia. Forward-looking statements are statements that
are not historical facts, nor assurances of future performance.
Instead, they are based on ContraFect’s current beliefs,
expectations and assumptions regarding the future of its business,
future plans, strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed under the caption “Risk Factors”
in ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel:
914-207-2300Email: mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel:
212-362-1200Email: lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2024 to May 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From May 2023 to May 2024